Ho­ba, a Dan­ish biotech from No­vo, rais­es $25M to crack in­to dif­fi­cult pain and hear­ing loss fields

No­vo Hold­ings-found­ed biotech Ho­ba Ther­a­peu­tics has raised $25 mil­lion in the first close of a Se­ries A fi­nanc­ing to bankroll its in­ves­ti­ga­tion­al med­i­cines for pain and hear­ing loss.

Copen­hagen-based Ho­ba, which got its start about sev­en years ago af­ter ac­quir­ing IP from Neu­roSearch spin­off Ns­Gene, has a non-opi­oid can­di­date that it hopes could fol­low in the foot­steps of Ver­tex Phar­ma­ceu­ti­cals’ lead­ing pro­gram. Boston-based Ver­tex is on the verge of a late-stage read­out for its can­di­date VX-548 for acute pain.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER